Acute Necrotizing Hemorrhagic Leukoencephalitis (ANHL)

Acute necrotizing hemorrhagic leukoencephalitis (ANHL) is a very rare, sudden, and severe inflammation of the brain’s white matter. Doctors also call it “Hurst disease” or “acute hemorrhagic leukoencephalitis (AHLE).” It is usually triggered by the immune system after a recent infection. In ANHL, the body’s defense cells attack small veins in the brain. This causes intense swelling, areas of tissue death (necrosis), and tiny bleeds (hemorrhages) around blood vessels. The damage spreads quickly, so symptoms worsen over hours to a few days. Because the illness moves fast and can cause pressure in the brain, it is a medical emergency with a high risk of complications if not treated immediately. Many experts view ANHL as a hyper-acute, more destructive cousin of ADEM (acute disseminated encephalomyelitis). PMCBioMed Central

Acute necrotizing hemorrhagic leukoencephalitis is a very rare, very fast brain disease. It causes sudden and severe inflammation in the brain’s white matter. The immune system attacks the brain after a recent infection, usually a cold or flu-like illness. Tiny blood vessels in the brain get injured. This leads to swelling, bleeding, and tissue death. Symptoms can worsen over hours to a few days. People may develop headache, fever, confusion, seizures, weakness, coma, or even death. Doctors think it is the most severe form of ADEM (acute disseminated encephalomyelitis). Because it moves quickly, urgent care in an ICU is needed. High-dose steroids and other immune therapies are often used early. Despite treatment, the condition can be life-threatening, so fast action matters. PubMed

---

Other names

ANHL is known by several names in the medical literature. The most common are Acute Hemorrhagic Leukoencephalitis (AHLE) and Hurst disease (after Dr. Weston Hurst, who first described it in 1941). You may also see Weston-Hurst syndrome, acute hemorrhagic leukoencephalopathy, or acute necrotizing hemorrhagic encephalitis/leukoencephalitis used in case reports. These labels describe the same core process: explosive inflammation of brain white matter with bleeding around small veins and rapid tissue breakdown. The different terms reflect history, preferred wording in journals, and whether the author emphasizes bleeding (“hemorrhagic”), tissue death (“necrotizing”), or white matter injury (“leukoencephalitis/leukoencephalopathy”). RadiopaediaPMC

Both conditions are post-infectious inflammatory diseases of the brain. ADEM is serious but usually milder and more common in children. ANHL is rarer, strikes mainly adults, and is much more aggressive. Under the microscope, ANHL shows neutrophil-rich inflammation, small-vessel necrosis, and perivascular hemorrhage, while classic ADEM shows mostly lymphocytes without vessel necrosis or bleeding. On MRI, ANHL lesions are larger, more edematous, and more likely to include visible blood products. Mortality is substantially higher in ANHL. WJGNetDNB

---

Types

There is no single official “type” list for ANHL. Doctors usually group cases by patterns that help with diagnosis and care. These patterns are descriptive, not strict rules:

1) By trigger

• Para-/post-infectious ANHL. Most common pattern. Follows a viral or (less often) bacterial illness by days to weeks. The immune system misfires and attacks the brain’s myelin and small vessels. PMCBioMed Central

• Post-vaccination ANHL (very rare). Timing suggests an immune reaction after vaccination; evidence remains limited to case reports. American Academy of Neurology

2) By tempo

• Hyperacute fulminant. The classic Weston-Hurst presentation: symptoms escalate over hours to a couple of days, often with coma and severe brain swelling. Radiopaedia

• Subacute severe. Slower ramp-up over several days, still dangerous but occasionally allows a slightly longer diagnostic window. Frontiers

3) By anatomic emphasis

• Cerebral-predominant. Most cases; large hemispheric white-matter lesions with mass effect.

• Brainstem/cerebellar-involved. Less common; may cause ataxia, dysarthria, or breathing problems. PMC

4) By radiologic pattern

• Hemorrhagic, ring-enhancing tumefactive lesions with marked edema.

• Diffuse confluent white-matter injury with microhemorrhages on susceptibility-weighted MRI. WJGNet

---

Causes

ANHL is best understood as an immune-mediated reaction, not a direct brain infection. Below are reported or suspected triggers. Each item explains the simple “why”:

1. Influenza (A or B). After the flu, the immune system can mistakenly attack myelin and small vessels in the brain. PMC

2. SARS-CoV-2 (COVID-19). Reports link COVID-19 to ANHL, likely through immune activation and endothelial injury. American Academy of Neurology

3. Mycoplasma pneumoniae. This atypical bacterium is a well-described trigger; molecular mimicry is suspected. PMC

4. Measles. Post-infectious demyelination after measles can rarely take a hemorrhagic, necrotizing form. BioMed Central

5. Mumps and rubella. Similar post-viral immune responses have been described in demyelinating syndromes. BioMed Central

6. Varicella-zoster virus (chickenpox). Vascular and immune effects may set off perivascular damage. BioMed Central

7. Epstein–Barr virus (EBV). EBV activates B- and T-cells intensely; in rare cases the reaction spills into brain white matter. PMC

8. Cytomegalovirus (CMV). Severe immune activation in susceptible hosts may precipitate ANHL-like injury. PMC

9. Adenovirus and enteroviruses. Post-infectious demyelinating illnesses after these viruses are reported; rarely hemorrhagic. PMC

10. Seasonal coronaviruses (non-SARS-CoV-2). Para-infectious links have been noted in demyelinating syndromes. PMC

11. Streptococcal infections. Post-streptococcal immune phenomena are well known and may include CNS inflammation. PMC

12. Staphylococcal infections. Intense systemic inflammation can trigger immune-mediated brain injury in rare cases. PMC

13. Borrelia burgdorferi (Lyme). Rare case links suggest an immune-driven white-matter attack after infection. ScienceDirect

14. Hepatitis viruses. Case reports describe post-infectious demyelinating CNS disease after hepatitis infections. PMC

15. HIV seroconversion (rare, immune phase). Abrupt immune shifts may unmask inflammatory CNS reactions. PMC

16. Recent vaccination (various types; rare). Temporal association suggests an immune trigger in a few cases. American Academy of Neurology

17. Autoimmune predisposition. A background tendency to over-react immunologically may raise risk after infection. PMC

18. Genetic susceptibility (theory). No single gene is proven, but case clustering by age hints at inherited risk. Frontiers

19. Severe systemic inflammation or sepsis. “Cytokine storms” can injure brain vessels and myelin secondarily. ScienceDirect

20. Unknown trigger. In some people, we never find a clear cause; the pattern still fits ANHL. PMC

Important note: In all of these, the problem is the immune over-reaction, not the germ itself invading the brain (CSF cultures/PCR are usually negative). PMC

---

Symptoms

1. Fever. A temperature spike is common because the immune system is highly active. It often follows a cold or flu-like illness. WJGNet

2. Severe headache. Brain swelling stretches pain-sensitive structures, causing a deep, diffuse headache that may build quickly. WJGNet

3. Rapid confusion. People become disoriented or unable to think clearly within hours to a couple of days because white-matter pathways are disrupted. PMC

4. Drowsiness or coma. As swelling rises and lesions expand, alertness drops. Some patients become comatose without urgent care. Radiopaedia

5. Seizures. Inflamed tissue fires abnormally, leading to convulsions or brief staring spells. PMC

6. Weakness on one side (hemiparesis). Large lesions in one hemisphere can cut off motor signals to the opposite side. PMC

7. Speech problems. If the language network is involved, words may come out slurred or incorrect (dysarthria/aphasia). PMC

8. Balance trouble and clumsiness. Cerebellar or brainstem involvement causes unsteady walking and poor coordination. PMC

9. Vision changes. Swelling near visual pathways may cause blurry vision, blind spots, or trouble focusing. PMC

10. Nausea and vomiting. Rising pressure inside the skull stimulates vomiting centers and worsens headache. WJGNet

11. Neck stiffness or photophobia. Meningeal irritation can make the neck stiff and bright light painful. PMC

12. Behavior or personality change. Frontal-lobe swelling can cause agitation, impulsivity, or apathy. PMC

13. Numbness or tingling. Sensory pathways misfire when myelin is stripped away. PMC

14. Trouble swallowing or breathing. Brainstem involvement can threaten airway and breathing and needs ICU care. PMC

15. Very fast worsening. The hallmark is tempo: decline over hours to a few days, not weeks to months. Radiopaedia

---

Diagnostic tests

A) Physical exam

1) Vital signs and general exam. Doctors look for fever, high blood pressure, fast heart rate, and signs of severe illness or dehydration. These clues support a systemic immune reaction and possible brain swelling.

2) Full neurological exam. The clinician checks orientation, memory, speech, eye movements, facial strength, limb power, sensation, reflexes, and coordination. The pattern—multifocal deficits rather than a single stroke area—raises suspicion for ANHL. PMC

3) Funduscopic exam (looking at the back of the eye). Papilledema (swollen optic discs) can signal raised intracranial pressure from brain swelling.

4) Meningeal signs. Neck stiffness and light sensitivity support meningeal irritation, which often accompanies aggressive brain inflammation.

B) “Manual” bedside neurologic tests

5) Glasgow Coma Scale (GCS). This quick score measures eye opening, speech, and movement. Falling scores show declining brain function and can guide ICU decisions.

6) NIH Stroke Scale (NIHSS). Although designed for stroke, it helps quantify focal deficits (speech, facial droop, arm/leg weakness). A scattered pattern fits multifocal inflammatory disease rather than one artery blockage.

7) Coordination tests (finger-to-nose, heel-to-shin). Errors point to cerebellar or white-matter pathway damage.

8) Gait and Romberg tests. Unsteady stance or veering suggests sensory or cerebellar involvement from white-matter injury.

C) Laboratory and pathological tests

9) Basic blood work (CBC, CMP, CRP/ESR). Many patients show a high white blood cell count and elevated inflammatory markers. These are non-specific but show the body is “on fire” immunologically. ScienceDirect

10) Infectious workup (blood cultures, respiratory PCR panels, serology). The aim is to find or exclude triggers like influenza, SARS-CoV-2, or Mycoplasma while proving the brain is not directly infected. A positive nasal PCR with negative CSF studies supports a para-infectious process. ScienceDirect

11) Lumbar puncture (CSF analysis). In ANHL, CSF often shows neutrophilic pleocytosis early, high protein, and no bacteria/viruses on culture/PCR. Sometimes the CSF is briefly normal early on. Red cells may appear from hemorrhagic lesions. Wiley Online LibraryMedlink

12) CSF/serum autoimmune panels. These tests look for other treatable inflammatory diseases (e.g., NMOSD/MOGAD) that can mimic ANHL. A negative panel with the right MRI pattern strengthens the ANHL diagnosis.

13) Serum myelin basic protein (optional, if available). Elevated levels can reflect active myelin breakdown during fulminant demyelination.

14) Brain biopsy (rare, targeted). When the diagnosis is uncertain, a neurosurgeon may remove a tiny piece of tissue. Pathology shows perivascular neutrophils, vessel wall necrosis, hemorrhage, and demyelination—the classic ANHL signature that separates it from ADEM and many infections or tumors. PMCWJGNet

D) Electrodiagnostic tests

15) Electroencephalogram (EEG). EEG often shows diffuse slowing in encephalopathy and can detect non-convulsive seizures, which are common in severe inflammatory brain disease. This guides anti-seizure treatment. PMC

16) Evoked potentials (selected cases). Visual or somatosensory evoked responses can demonstrate disrupted conduction through inflamed white-matter tracts, supporting demyelination when imaging is equivocal.

E) Imaging tests

17) MRI brain with and without gadolinium (core test). MRI typically shows large, multifocal white-matter lesions with extensive edema, ring or patchy enhancement, and blood products on susceptibility-weighted sequences. Diffusion restriction may mark active injury. This pattern, plus the clinical picture, strongly suggests ANHL. WJGNet

18) Susceptibility-weighted imaging (SWI). SWI is especially good at detecting tiny bleeds (microhemorrhages) around veins—highly supportive of ANHL rather than classic ADEM. WJGNet

19) CT head (initial screen). CT is fast and can show large areas of low density (edema) or frank hemorrhage. It is useful in emergencies but can be normal early, so a normal CT does not rule out ANHL. Medlink

20) Vascular imaging (CTA/MRA/MRV as needed). These tests rule out stroke, vasculitis of large vessels, or venous sinus thrombosis and help confirm that the problem is primarily inflammatory and perivascular at the micro-vessel level.

Non-pharmacological treatments

Important: In the acute phase, most care happens in an ICU under a neurologist/critical care team. The first priority is airway, breathing, circulation, and brain edema control. The non-drug items below include acute ICU measures and rehabilitation for survivors. Where evidence is limited or extrapolated from general neuro-ICU/encephalitis care, I say so.

Acute ICU & supportive measures (first days)

1. Airway protection and mechanical ventilation
   Description (≈150 words): If consciousness drops or swallow is unsafe, doctors secure the airway and start a ventilator. This prevents aspiration and stabilizes oxygen and carbon dioxide levels. Good oxygenation reduces extra brain injury. Controlled ventilation allows careful carbon dioxide management, which can affect brain vessel size and pressure. Sedation ensures comfort and synchrony with the ventilator. Family presence and clear communication lower stress during this critical time.
   Purpose: Protect lungs and brain while the inflammation is treated.
   Mechanism: Stabilizes gas exchange and limits secondary brain damage from low oxygen or high CO₂.
   Benefits: Lowers pneumonia and aspiration risk; buys time for immune therapy to work.

2. Intracranial pressure (ICP) control protocols
   Description: Nurses and doctors use head-up positioning, neutral neck alignment, fever control, quiet environment, and avoidance of coughing or straining to limit spikes in ICP. Hyperosmolar therapy (mannitol or hypertonic saline—drug items covered later) is added if needed; an external ventricular drain may be placed for monitoring/drainage (a procedure).
   Purpose: Prevent herniation and protect brain tissue.
   Mechanism: Reduces cerebral edema and improves cerebral perfusion pressure.
   Benefits: Decreases risk of sudden neurologic decline and death.

3. Early EEG monitoring
   Description: Continuous EEG detects silent seizures and guides anti-seizure therapy.
   Purpose: Prevent ongoing neuronal injury from unrecognized status epilepticus.
   Mechanism: Real-time brain electrical monitoring.
   Benefits: Better seizure control; safer sedation weaning.

4. Temperature management
   Description: Fever makes inflammation worse. Teams treat fever with cooling blankets and acetaminophen, and manage shivering.
   Purpose: Keep temperature normal.
   Mechanism: Lowers metabolic demand and cytokine activity.
   Benefits: May improve outcomes and comfort.

5. DVT and pressure-injury prevention
   Description: Use compression devices, position changes, skin checks, and early passive range-of-motion.
   Purpose: Prevent blood clots and bedsores.
   Mechanism: Improves venous return and preserves skin integrity.
   Benefits: Lower complication rates.

Rehabilitation & physiotherapy (after stabilization)

6. Early mobilization with physical therapy (PT)
   Description (≈150 words): As soon as it is safe, PT starts in bed: rolling, sitting at edge, standing with support, and short ambulation. Sessions are short and frequent. Therapists watch for fatigue and orthostatic hypotension. Goals are written in simple steps. Family is trained to help with safe transfers.
   Purpose: Restore strength and endurance.
   Mechanism: Neuroplasticity improves when practice starts early.
   Benefits: Shorter hospital stays; better independence.

7. Task-specific gait training
   Purpose: Improve walking safety and speed.
   Mechanism: Repetitive stepping patterns stimulate spinal and cortical circuits.
   Benefits: Better balance; fewer falls.

8. Constraint-induced movement therapy (when one side is weak)
   Purpose: Overcome “learned nonuse.”
   Mechanism: Restrict stronger limb to force practice with weaker limb.
   Benefits: Improves arm/hand function.

9. Balance and vestibular therapy
   Purpose: Reduce dizziness and falls.
   Mechanism: Habituation and gaze-stabilization exercises.
   Benefits: Safer mobility.

10. Speech-language therapy for swallowing (dysphagia)
    Purpose: Prevent aspiration and improve nutrition.
    Mechanism: Swallow exercises, texture modifications, and compensatory strategies.
    Benefits: Fewer pneumonias; better intake.

11. Speech-language therapy for communication
    Purpose: Recover speech and language.
    Mechanism: Aphasia and dysarthria programs with home practice.
    Benefits: Better participation and quality of life.

12. Occupational therapy for activities of daily living (ADLs)
    Purpose: Relearn dressing, grooming, feeding, writing, and device use.
    Mechanism: Task analysis and graded practice.
    Benefits: More independence at home.

13. Cognitive rehabilitation
    Purpose: Improve attention, memory, and executive skills after encephalopathy.
    Mechanism: Structured drills, compensatory tools (planners, phone apps).
    Benefits: Return to school/work sooner.

14. Spasticity management (non-drug)
    Purpose: Reduce stiffness and contractures.
    Mechanism: Stretching, splints, positioning, heat/cold.
    Benefits: Comfort and mobility.

15. Respiratory physiotherapy
    Purpose: Clear secretions after ventilation.
    Mechanism: Breathing exercises, incentive spirometry, airway clearance techniques.
    Benefits: Fewer infections; better stamina.

16. Vision therapy and oculomotor training
    Purpose: Help double vision and tracking problems.
    Mechanism: Eye movement drills, prisms (with optometry).
    Benefits: Reading and navigation improve.

17. Pain and headache non-drug care
    Purpose: Reduce discomfort that limits therapy.
    Mechanism: Hydration, sleep hygiene, relaxation, heat/cold packs, posture work.
    Benefits: Better function without excess meds.

18. Fatigue management and energy conservation
    Purpose: Balance activity and rest.
    Mechanism: Pacing, prioritizing tasks, planned breaks.
    Benefits: More total activity across the day.

19. Return-to-driving/work assessment
    Purpose: Safety and readiness check.
    Mechanism: Cognitive, visual, and motor testing with simulation when available.
    Benefits: Lowers accident risk; smoother transitions.

20. Family and caregiver training
    Purpose: Teach safe transfers, exercises, and communication strategies.
    Mechanism: Hands-on sessions and written plans.
    Benefits: Fewer readmissions; better home outcomes.

Mind-body and educational supports

21. Psychoeducation for patient/family
    Description (≈150 words): The team explains the diagnosis, expected course, warning signs, and the plan. Simple language and pictures help. Families learn how to track symptoms, manage medications, and schedule follow-ups.
    Purpose: Reduce fear and improve adherence.
    Mechanism: Knowledge improves decision-making and reduces stress.
    Benefits: Better recovery and satisfaction.

22. Stress-reduction practices (mindfulness, guided breathing)
    Purpose: Lessen anxiety and help sleep.
    Mechanism: Lowers sympathetic arousal; may modulate inflammatory pathways indirectly.
    Benefits: Better mood and participation in therapy.

23. Sleep optimization routine
    Purpose: Protect brain healing.
    Mechanism: Dark nights, light days, noise control, consistent schedule.
    Benefits: Better cognition and energy.

24. Nutrition counseling (non-drug)
    Purpose: Ensure adequate protein and calories for recovery.
    Mechanism: Registered dietitian sets targets; texture changes for dysphagia.
    Benefits: Strength and wound healing.

25. Peer support and counseling
    Purpose: Address grief, adjustment, and PTSD after ICU.
    Mechanism: Support groups, psychology referrals.
    Benefits: Lower depression and caregiver burnout.

Note on “mind-body gene therapy”: There is no approved gene therapy or “mind-body gene therapy” for AHLE. Mind-body practices help coping and sleep but do not edit genes. Experimental gene or cell therapies should only occur in clinical trials.

---

Drug treatments

Safety note: Doses below are typical ranges used in encephalitis/ADEM protocols and must be individualized by physicians. Evidence in AHLE is mostly case reports/series and expert opinion; rapid specialist care is essential.

1. IV methylprednisolone (high-dose steroid)
   Class: Corticosteroid.
   Typical dose/time: 1,000 mg IV daily for 3–5 days, then taper to oral prednisone as directed.
   Purpose: Blunt the immune attack and reduce edema.
   Mechanism: Broad anti-inflammatory and anti-edema effects; stabilizes blood–brain barrier.
   Side effects: High blood sugar, infection risk, mood change, GI upset.
   Evidence: First-line in ADEM/AHLE protocols; early aggressive therapy recommended. PubMed

2. Intravenous immunoglobulin (IVIG)
   Class: Pooled immunoglobulins.
   Typical dose: 2 g/kg total over 2–5 days.
   Purpose: Modulate autoantibodies and immune signaling.
   Mechanism: Fc-receptor blockade, neutralization of pathologic antibodies, anti-inflammatory cytokine effects.
   Side effects: Headache, aseptic meningitis, thrombosis risk, kidney strain (rare).
   Evidence: Case reports show improvement, including after PLEX failure in pediatrics. PMC

3. Therapeutic plasma exchange (PLEX)
   Class: Apheresis procedure (drug-adjacent therapy).
   Typical course: 5–7 exchanges over 7–14 days.
   Purpose: Remove pathogenic antibodies and inflammatory mediators.
   Mechanism: Plasma removal and replacement.
   Side effects: Line complications, hypotension, bleeding, infections.
   Evidence: Case series suggest benefit in severe AHLE/ADEM when steroids/IVIG insufficient. Experts@MinnesotaKarger

4. Acyclovir (empiric)
   Class: Antiviral.
   Typical dose: 10 mg/kg IV every 8 hours pending HSV testing.
   Purpose: Cover herpes encephalitis until PCR returns negative.
   Mechanism: Inhibits viral DNA polymerase.
   Side effects: Kidney injury risk (hydrate), neurotoxicity at high levels.
   Evidence: Standard empiric coverage in suspected encephalitis while awaiting results.

5. Broad-spectrum antibiotics (empiric)
   Class: Antibacterials (e.g., ceftriaxone + vancomycin per local protocols).
   Typical course: Until bacterial meningitis/encephalitis is excluded.
   Purpose/Mechanism: Rapidly treat possible bacterial causes.
   Side effects: Allergy, C. difficile risk.
   Evidence: Standard encephalitis bundle on presentation.

6. Levetiracetam (anti-seizure)
   Class: Antiepileptic.
   Typical dose: 1,000–3,000 mg IV loading; then 1,000–1,500 mg twice daily (adjusted).
   Purpose: Stop seizures and prevent recurrence.
   Mechanism: Modulates synaptic vesicle protein SV2A.
   Side effects: Somnolence, mood irritability.
   Evidence: Widely used in encephalitis-related seizures.

7. Hypertonic saline (3%)
   Class: Osmotherapy.
   Typical use: Boluses or infusions targeting safe sodium range per ICP protocol.
   Purpose: Reduce brain swelling.
   Mechanism: Osmotic shift draws water out of brain tissue.
   Side effects: Hypernatremia, fluid shifts.
   Evidence: Standard neuro-ICU practice for malignant edema.

8. Mannitol
   Class: Osmotic diuretic.
   Typical dose: 0.25–1 g/kg IV bolus as needed for ICP spikes.
   Purpose/Mechanism: Osmotic brain dehydration.
   Side effects: Kidney stress, hypotension if overused.
   Evidence: Traditional ICP therapy in acute brain swelling.

9. Cyclophosphamide (rescue immunosuppression)
   Class: Alkylating agent.
   Dose: Regimens vary (e.g., 500–1,000 mg/m² IV once, sometimes repeated).
   Purpose: Rescue therapy when steroids/IVIG/PLEX fail.
   Mechanism: Profound B- and T-cell suppression.
   Side effects: Infection risk, cytopenias, hemorrhagic cystitis (give mesna).
   Evidence: Reported in refractory ADEM/AHLE cases; low-quality evidence.

10. Rituximab (rescue immunotherapy)
    Class: Anti-CD20 monoclonal antibody.
    Dose: Commonly 375 mg/m² weekly × 4 or 1,000 mg × 2 two weeks apart.
    Purpose/Mechanism: Depletes B cells that produce pathogenic antibodies.
    Side effects: Infusion reactions, hypogammaglobulinemia, infection risk.
    Evidence: Used in steroid/PLEX/IVIG-refractory demyelinating disease; case-level data in AHLE.

11. Tocilizumab (select refractory cytokine-storm cases)
    Class: IL-6 receptor blocker.
    Dose: 4–8 mg/kg IV single dose, repeat per specialist.
    Purpose: Damp cytokine storm in fulminant cases (off-label).
    Side effects: Infection risk, liver enzyme rise.
    Evidence: Limited; consider only in multidisciplinary, refractory scenarios.

12. Mycophenolate mofetil (maintenance, selected)
    Class: Antimetabolite immunosuppressant.
    Dose: 500–1,000 mg twice daily (if used).
    Purpose: Rarely used after recovery to prevent relapse if ADEM-like relapse risk is judged high.
    Side effects: Cytopenias, GI upset, infections.
    Evidence: Extrapolated from other demyelinating disease; not routine.

13. Azathioprine (maintenance, selected)
    Class: Antimetabolite.
    Dose: 1–2 mg/kg/day with TPMT testing.
    Purpose/Mechanism: Steroid-sparing immunosuppression.
    Side effects: Cytopenias, hepatotoxicity.
    Evidence: Limited and not standard for AHLE.

14. Acetaminophen/NSAIDs (supportive for fever and pain)
    Class: Analgesic/antipyretic.
    Dose: Per standard dosing.
    Purpose/Mechanism: Comfort and fever control.
    Side effects: Liver/stomach risks with excess or in contraindicated patients.
    Evidence: Symptom control only.

15. Prophylaxis meds (ICU bundle):
    Examples: DVT prophylaxis (heparin if safe), stress-ulcer prophylaxis (PPI/H2 blocker), bowel regimen, and antibiotics for proven infections.
    Purpose: Prevent ICU complications.
    Evidence: Standard critical-care practice.

Cost and logistics note: In health-system analyses, PLEX can be more cost-effective than IVIG in some neurologic settings, but availability and patient factors drive the choice. BioMed Central

---

Dietary molecular supplements

These can support general neuro-recovery, inflammation control, or nutrition. They do not treat AHLE itself. Interactions with immune therapy are possible; always clear with the medical team.

1. High-quality protein (whey or medical nutrition formulas)
   Dose: To meet dietitian-set protein goals (often 1.2–1.5 g/kg/day in rehab).
   Function/mechanism: Supplies amino acids for repair; supports immune function.

2. Omega-3 fatty acids (EPA/DHA)
   Dose: Commonly 1–2 g/day combined EPA+DHA.
   Function: Anti-inflammatory lipid mediators; may modestly aid cognitive recovery.

3. Vitamin D3
   Dose: 1,000–2,000 IU/day (or per lab-guided repletion).
   Function: Immune modulation and bone health during steroid therapy.

4. B-complex (esp. B1, B6, B12)
   Dose: Per label or deficiency correction.
   Function: Nerve metabolism; corrects deficits that worsen neuropathy or fatigue.

5. Magnesium
   Dose: 200–400 mg/day as tolerated.
   Function: May help sleep and headaches; supports nerve and muscle function.

6. Probiotics (ICU/antibiotic periods—only if safe)
   Dose: Per product; avoid in immunocompromise unless approved.
   Function: Gut microbiome support; may reduce antibiotic-associated diarrhea.

7. Creatine
   Dose: 3–5 g/day if kidneys are healthy.
   Function: Cellular energy buffer; studied in neuro-rehab contexts.

8. Coenzyme Q10
   Dose: 100–200 mg/day.
   Function: Mitochondrial support; antioxidant properties.

9. Curcumin (with piperine for absorption)
   Dose: 500–1,000 mg/day standardized extract.
   Function: Anti-inflammatory signaling; check interactions and bleeding risk.

10. Zinc (short-term if low)
    Dose: ~15–30 mg/day for 2–3 months if deficient.
    Function: Immune function and wound healing.

---

Immunity-booster / regenerative / stem-cell drugs

There is no approved stem-cell or gene therapy for AHLE. The items below are context notes to avoid misinformation.

1. Autologous hematopoietic stem cell transplant (AHSCT)
   Use: Not a treatment for AHLE; sometimes used in aggressive MS or autoimmune disorders.
   Mechanism: Immune “reset” after chemotherapy.
   Status: Not recommended for AHLE outside clinical trials.

2. Mesenchymal stromal cells (experimental)
   Use: Investigational for neuroinflammation.
   Mechanism: Paracrine immunomodulation.
   Status: Trial-only; not standard.

3. Intravenous immunoglobulin (listed above)
   Note: Sometimes informally called “immune booster,” but it is immune-modulating therapy, not a vitamin or stimulant.

4. Rituximab (listed above) – targeted B-cell depletion; rescue only.

5. Cyclophosphamide (listed above) – profound immunosuppression; rescue only.

6. Tocilizumab (listed above) – cytokine modulation; select refractory cases only.

Bottom line: If you see claims of “stem cell cures” for AHLE, be cautious. Discuss only within regulated clinical trials.

---

Surgeries or procedures

1. External ventricular drain (EVD)
   Procedure: A catheter is placed into the ventricles to monitor ICP and drain CSF.
   Why: Control life-threatening pressure spikes and monitor ICP continuously.

2. Decompressive hemicraniectomy
   Procedure: Temporarily remove a skull segment to allow the swollen brain to expand.
   Why: Prevent herniation and death in malignant edema when medical therapy fails.

3. Brain biopsy
   Procedure: Take a small tissue sample.
   Why: When diagnosis remains uncertain and pathology will change treatment.

4. Tracheostomy
   Procedure: Surgical airway in the neck after prolonged ventilation.
   Why: Improve comfort and facilitate weaning and airway care.

5. Feeding tube (PEG)
   Procedure: Place a tube directly into the stomach.
   Why: Long-term nutrition when swallowing is unsafe.

---

Prevention tips

1. Treat respiratory infections early and follow return-to-care instructions.

2. Follow public-health advice on vaccination to reduce severe infections that can cause encephalitis (overall benefit outweighs rare adverse events).

3. Hand hygiene and avoiding sick contacts during outbreaks.

4. Manage chronic illnesses (diabetes, autoimmune disease) with regular care.

5. Do not ignore new neurologic symptoms after infections—seek urgent care.

6. Use seatbelts/helmets and fall prevention, because brain injury worsens outcomes if encephalitis occurs.

7. Keep medication and allergy lists handy for emergency teams.

8. Maintain good sleep, nutrition, and exercise to support immune balance.

9. Avoid excess alcohol and illicit drugs that cloud neurologic assessment.

10. Have a primary clinician for quick access and guidance during viral seasons.

---

When to see doctors

• Sudden severe headache with fever.

• Confusion, unusual behavior, or new drowsiness.

• Any seizure or repeated vomiting with headache.

• New weakness, numbness, speech problems, or vision loss.

• Stiff neck with fever or rash.

• Rapid worsening over hours to a day after a recent infection.

---

What to eat and what to avoid

What to eat:

• Enough calories and high-quality protein every day (eggs, lean meats, dairy, legumes) to rebuild strength.

• Whole grains, fruits, and vegetables for fiber and micronutrients.

• Healthy fats (olive oil, nuts, fatty fish) for omega-3s.

• Plenty of fluids unless restricted by your doctor.

• If swallowing is unsafe, follow the speech therapist’s texture plan and dietitian’s formula plan.

What to avoid:

• Alcohol and recreational drugs.

• Very high-sugar ultra-processed foods that worsen fatigue and glucose swings (especially on steroids).

• Herbal products or supplements without your clinician’s approval (risk of interactions).

• Dehydration; skipping meals that lead to weakness during therapy.

---

FAQs

1. Is AHLE the same as ADEM?
   No. AHLE is considered the most severe ADEM-spectrum form, with more bleeding and swelling. PubMed

2. How fast does AHLE progress?
   It can worsen within hours to a few days. Early ICU care is critical. PubMed

3. What does the MRI show?
   Large white-matter lesions with edema and tiny hemorrhages; GRE/SWI highlight microbleeds. Radiopaedia

4. What is the chance of survival?
   Published reviews report high mortality overall, though survivors can recover well with early, aggressive treatment and rehabilitation. PMC

5. What treatments work best?
   Teams often start high-dose steroids, add IVIG or PLEX if needed, and treat complications. Evidence is mainly case-based. PubMedPMCExperts@Minnesota

6. Can antivirals or antibiotics cure AHLE?
   They treat infections that can look similar or co-exist. AHLE itself is immune-mediated, so immunotherapy is central.

7. Will I need brain surgery?
   Only if brain swelling is life-threatening or the diagnosis is unclear and biopsy is necessary.

8. Can AHLE come back?
   Relapse is uncommon but possible within an ADEM spectrum. Follow-up MRI and visits are important.

9. Is there a specific blood test for AHLE?
   No. The diagnosis relies on symptoms, MRI, CSF findings, and exclusion of infections. PubMed

10. What causes the bleeding?
    Severe small-vessel injury and inflammation lead to microhemorrhages and necrosis. Wiley Online Library

11. How long is recovery?
    Highly variable: weeks to months. Many need ongoing rehab.

12. Can children get AHLE?
    Yes, but it is rare in all ages.

13. Are there long-term effects?
    Some survivors have cognitive or motor deficits; others recover well with therapy.

14. Do supplements help?
    They do not treat AHLE but can support nutrition and rehab. Always clear with your clinician.

15. What should families focus on?
    Fast emergency evaluation, adherence to treatment, infection prevention, rehab engagement, and caregiver support.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 06, 2025.